Mebeverine

From Self-sufficiency
Revision as of 16:12, 12 September 2010 by Tuanomsoc (Talk) (grammar)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Mebeverine
300px
300px
Systematic (IUPAC) name
(RS)-4-(ethyl[1-(4-methoxyphenyl)propan-2-yl]amino)butyl 3,4-dimethoxybenzoate
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • UK: POM (Prescription only)
Identifiers
CAS Number 2753-45-9
ATC code A03AA04 (WHO)
PubChem CID 24896829
Chemical data
Formula C25H35NO5
Molar mass 466.01004 [g/mol][[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Mebeverine is a musculotropic antispasmodic drug without atropic side-effects whose major therapeutic role is in the treatment of irritable bowel syndrome. It is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965. It is manufactured and marketed as Colofac, Duspatal and Duspatalin by Solvay Pharmaceuticals.

Mebeverine is presented in the United Kingdom as a (135mg) tablet. Other strengths: 100mg tablet and 200mg capsule.

File:Mebeverine(Colofac) 135mg UK.jpg
Mebeverine(Colona) 135mg, Bought U.K.

Mode of action

Mebeverine is an antimuscarinic. Mebeverine belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, mebeverine has dual mode of action which normalizes the small bowel motility.

Indications

Spastic functional disturbances of the colon:

  • Irritable bowel syndrome in its primary form
  • Irritable bowel syndrome associated with organic lesions of the gastrointestinal tract such as; diverticulosis and diverticulitis, regional enteritis, disease of the gall bladder and gall ducts, gastric and duodenal ulcers, dysentery, and aspecific or specific inflammation of the digestive tract.
  • mebeverine should be taken 20 minutes before meals.

Adverse effects

Since 1978, 21 cases of severe adverse reactions to mebeverine were reported in the Netherlands.[1] Most reactions consisted of urticaria or maculopapular rash, sometimes accompanied by fever, polyarthritis, thrombopenia or angioedema.

Listed side effects

Very rarely, people taking this medicine may develop allergic reactions. These may include inflamed or reddened skin, itching or skin rashes. If you develop swelling of the face, lips and/or tongue, stop taking your tablets and contact your doctor immediately. If you notice these or any other side effects not mentioned in this leaflet, tell your doctor or a pharmacist.[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


ar:ميبفرين

de:Mebeverin pl:Mebeweryna pt:Mebeverina

ru:Мебеверин
  1. in 't Veld BA, van Puyenbroek E, Stricker BH. (1997). Hypersensitivity reactions to use of mebeverine. pp. 1392–5.  Ned Tijdschr Geneeskd. 1997 Jul 12;141(28):1392-5. Hypersensitivity reactions to use of mebeverine [1] pubmed: 9380201
  2. Colofac Patient leaflet sheet http://emc.medicines.org.uk/medicine/2531/PIL/Colofac+Tablets+135mg/